The pediatric interventional cardiology market is growing at a significant rate, due to the increasing instances of heart diseases in children and the rising technological advancements in the field. Other factors driving the pediatric interventional cardiology market include increasing awareness among the population, increased preference of minimally invasive procedures over conventional surgeries, and the rising number of congenital disorders. However, stringent regulatory policies, expensive treatments, and therapies are likely to hamper the growth of the pediatric interventional cardiology market.

Key Market Trends

Stents is Expected to Hold Significant Share in this Market

There are different types of stents available in the market for the pediatric interventional cardiology procedures. Bare Stent, drug-eluting stent, bio-absorbable stent are few among them. According to a new research study published in Catheterization and Cardiovascular Interventions, the official journal of The Society for Cardiovascular Angiography and Interventions (SCAI) conducted by Rady Children’s researchers found coronary stent implantation to be a feasible and safe palliative option for children fifteen months and younger.

A bare stent is used to widen any narrowed coronary artery while performing angioplasty. A bare stent is preferred if the blocked vessel is large and the blockages are small. A bare-metal stent is quite economical and helps in fast vascular healing, with no risk of thrombosis.

Drug-eluting stents are used for stenoticarteries, in order to prevent fibrosis by releasing drugs. Unlike bare stents, these help in suppressing restenosis or relocking of the artery after angioplasty and decrease the chances of repeating the angioplasty.

A bio-absorbable stent is made up of a metal or a polymer that is dissolved or absorbed into the body. It is highly advanced than, both, bare stent and drug-eluting stent. Bio-absorbable stents do not cause permanent metal prosthesis. Thrombosis and restenosis are prevented, as the stent disappears.

Asia Pacific is the fastest growing region in Pediatric Interventional Cardiology Market

North America region has the largest share in global pediatric interventional cardiology market. This can be attributed to the rising incidences of CHDs, nationwide. As per the Centre for Disease Control (CDC), congenital heart defect (CHD) is the most common type of birth defects, which affects nearly 1%, or about 40,000 births per year. The prevalence of some of the mild CHDs is increasing, while the prevalence of other types has remained stable. At least 15% of all CHDs are associated with genetic conditions. Other prime drivers are rising demand for less invasive procedure for high-risk patients, growing prevalence of mitral regurgitation, severe aortic stenosis disorder, and also factors, such as shorter recovery time, less stay in hospitals, favorable outcomes with transcatheter prosthetic valve implantation, and other technological advancements are likely to boost the growth of the Pediatric Interventional Cardiology Market in North America region.

Competitive Landscape

Market players in Global Pediatric Interventional Cardiology Market are focusing on the expansion of their product portfolios by adopting inorganic growth strategies such as acquisitions, mergers and partnerships. Major players in Global Pediatric Interventional Cardiology Market are Abbott, Boston Scientific Corporation, Cardinal Health, Edwards Lifesciences Corporation, GE Healthcare, W. L. Gore & Associates, Medtronic, NuMED Inc., and Siemens AG among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support